Drug mineralization type gel as well as preparation method and application thereof

The drug mineralization gel formed by mixing sodium alendronate with Ca2+ solves the problems of burst release and biocompatibility of existing drug sustained-release gels, achieving excellent lubrication performance and long-term drug sustained release, and is suitable for the treatment of osteoarthritis.

CN122005953APending Publication Date: 2026-05-12LANZHOU INSTITUTE OF CHEMICAL PHYSICS CHINESE ACADEMY OF SCIENCES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202610223247.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-02-25
Publication Date
2026-05-12

AI Technical Summary

Technical Problem

Existing drug-release gels suffer from problems such as sudden drug release, low loading capacity, poor stability, and poor biocompatibility, and therefore cannot effectively relieve osteoarthritis symptoms.

Method used

A metal-organic framework-like crystal was formed by mixing sodium alendronate with Ca2+, and a HA-ADA-Ca hydrogel was formed through dynamic mechanical changes. The coordination of the carboxylic acid group and phosphonic acid group of sodium hyaluronate was used to promote the deposition of calcium phosphate mineralization phase, thus preparing a drug mineralization gel.

Benefits of technology

The prepared drug mineralization gel has excellent lubrication properties, long-lasting drug release capability and good biocompatibility, which can effectively reduce joint surface friction, relieve joint inflammation and improve treatment effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122005953A_ABST
    Figure CN122005953A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biomedical gel material preparation, and discloses medicine mineralized gel as well as a preparation method and application thereof. The preparation method of the medicine mineralization type gel comprises the following steps: dropwise adding a NaOH aqueous solution into an alendronate sodium aqueous solution to obtain a mixture; mixing the mixture with sodium hyaluronate to obtain a viscous liquid; dropwise adding the viscous liquid into a CaCl2 aqueous solution, and stirring and mixing to obtain hydrogel; and incubating the hydrogel to obtain the drug mineralization type gel. The medicine mineralized gel prepared by the invention has excellent injectability, lubricating property, long-acting medicine slow release capacity and good biocompatibility, can quickly form gel after being injected into an articular cavity, not only plays roles in lubricating joints and reducing friction, but also can relieve joint inflammation and effectively improve joint functions, and can be used for treating joint inflammation. The application value in the field of osteoarthritis treatment is extremely high.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biomedical gel materials technology, specifically to a drug mineralization gel, its preparation method, and its application. Background Technology

[0002] Osteoarthritis is a common degenerative joint disease, mainly characterized by wear and tear of articular cartilage, reduction of synovial fluid in the joint cavity, and joint inflammation. Clinical treatment often involves injecting joint lubricants to relieve symptoms. Traditional joint lubricants, such as hyaluronic acid gel, can temporarily improve joint lubrication, but they lack the therapeutic effect of drugs and cannot effectively relieve joint inflammation. On the other hand, simple drug injection treatment has a short retention time in the joint cavity and is easily metabolized, resulting in limited therapeutic effects.

[0003] Injectable gels with sustained-release properties combine the convenience of injectable materials with the long-lasting effect of drug release, making them a hot research topic. However, existing sustained-release gels mostly use physical embedding methods to load drugs, which suffers from problems such as burst release, low loading capacity, and poor stability. Furthermore, some gel materials have poor biocompatibility, easily triggering foreign body reactions after injection into the joint cavity, and their gelation rate and mechanical properties are difficult to match the physiological environment requirements within the joint cavity. Therefore, developing an injectable gel that combines excellent lubrication properties, long-lasting drug release capability, and good biocompatibility is of great significance for the effective treatment of osteoarthritis. Summary of the Invention

[0004] Therefore, the purpose of this invention is to provide a drug mineralization gel, its preparation method, and its application. The drug mineralization gel provided by this invention possesses excellent lubrication properties, long-lasting drug release capability, and good biocompatibility, and exhibits excellent therapeutic effects on osteoarthritis.

[0005] To achieve the above-mentioned objectives, the present invention provides the following technical solution: This invention provides a method for preparing a drug mineralization gel, comprising the following steps: An aqueous solution of hydroxide was added dropwise to an aqueous solution of sodium alendronate to obtain a mixture; The mixture was then mixed with sodium hyaluronate to obtain a viscous liquid; The viscous liquid was added dropwise to an aqueous calcium source solution and stirred to obtain a hydrogel. The hydrogel was incubated to obtain a drug-mineralized gel.

[0006] Preferably, the hydroxide in the aqueous hydroxide solution includes one or more of sodium hydroxide, potassium hydroxide, lithium hydroxide, and calcium hydroxide; The concentration of the hydroxide aqueous solution is 50~100 mg / mL.

[0007] Preferably, the concentration of the sodium alendronate aqueous solution is 10~30 mg / mL.

[0008] Preferably, the calcium source in the calcium source aqueous solution includes one or more of calcium chloride, calcium nitrate, and calcium acetate; The concentration of the calcium source aqueous solution is 400~600 mg / mL.

[0009] Preferably, the pH value of the system during the preparation of the mixture is 7-8.

[0010] Preferably, the number-average molecular weight of the sodium hyaluronate is 1,000,000 to 1,500,000; The mass concentration of sodium hyaluronate in the viscous liquid is 30~60 mg / mL.

[0011] Preferably, the incubation temperature is 25~45℃ and the incubation time is 0~7h.

[0012] The present invention also provides a drug mineralization gel prepared by the preparation method described in the above technical solution.

[0013] This invention also provides the application of the drug mineralization gel described in the above technical solution in the preparation of biomedical gel materials.

[0014] Preferably, the biomedical gel material includes an injectable joint lubricant.

[0015] This invention utilizes sodium alendronate (ADA) and Ca 2+ Mixing to form ADA-Ca 2+ Metal-organic framework (MOF)-like crystals, hydrogel (HA-ADA-Ca), undergo dynamic mechanical changes during incubation. The Ca in the HA-ADA-Ca hydrogel... 2+ The carboxylic acid group (-COO-) of sodium hyaluronate (HA) and the phosphonic acid group (-PO3) of sodium alendronate (ADA) 2- All of them undergo coordination, and the introduction of ADA promotes the deposition of calcium phosphate mineralization phase through P-Ca interaction, thus endowing the drug mineralized gel with mechanical properties and biological activity.

[0016] The drug mineralization gel prepared by this invention has excellent lubrication properties. Due to the hydrophilicity of the polymer chain (sodium hyaluronate) and the ability of the gel network to bind water, the hydrogel can form a hydrated film layer during the lubrication process, reducing the coefficient of friction and thus achieving a good lubrication effect. This effectively reduces the coefficient of friction on the joint surface and reduces cartilage wear.

[0017] The drug mineralization gel prepared by this invention has excellent injectability, is fluid at room temperature, and can be easily injected into the joint cavity using a conventional syringe, making the operation convenient and minimally invasive.

[0018] The drug mineralization gel prepared by this invention has stable drug sustained-release properties. The drug alendronate sodium can be stably loaded through mineralization and gradually released as the gel slowly degrades, thus prolonging the drug's action time and improving the therapeutic effect.

[0019] The drug mineralization gel prepared by this invention has good biocompatibility. All raw materials used are biocompatible materials with no obvious cytotoxicity and are not likely to cause foreign body reaction in the joint cavity after injection.

[0020] The drug-mineralized gel prepared by this invention possesses excellent injectability, lubrication properties, long-lasting drug release capability, and good biocompatibility. It exhibits excellent therapeutic effects on osteoarthritis and can be used to prepare drug-mineralized gels, particularly injectable joint lubricants. When injected into the joint cavity via a syringe, the drug-mineralized gel prepared by this invention rapidly gels, reducing the joint surface friction coefficient to 0.02-0.04. The drug is released continuously as the gel slowly degrades, without any burst release issues. This invention not only lubricates joints and reduces friction but also alleviates joint inflammation, effectively improving joint function, and has extremely high application value in the treatment of osteoarthritis. Furthermore, the raw materials used in this invention meet safety standards (chondrocyte survival rate ≥80%, no foreign body reaction), simultaneously achieving lubrication, anti-inflammation, and cartilage repair, demonstrating excellent prospects for widespread application.

[0021] The preparation method provided by this invention is simple in process, easy to operate, and has low production cost, making it suitable for industrial production. Attached Figure Description

[0022] Figure 1 This is a schematic diagram of the preparation process of the drug mineralization gel in this invention; Figure 2 Comparison of the modulus of the drug mineralization gels prepared in Examples 1-3 at different temperatures; Figure 3 Comparison of modulus of the drug mineralization gels prepared in Examples 4-6 after incubation at 37°C for different times; Figure 4 The statistical results of modulus changes of the drug mineralization gels prepared in Examples 4-6 after incubation at 37°C for different times; Figure 5 Comparison of the compressibility of the drug mineralized gels prepared in Examples 4-6; Figure 6 The statistical results of stress and modulus of the drug mineralization gels prepared in Examples 4-6 are as follows; Figure 7 Comparison of the lubrication properties of the drug mineralization gel prepared in Example 6 under different loads; Figure 8A comparison diagram of the lubrication performance of the drug mineralization gel prepared in Example 6 at different frequencies; Figure 9 Comparison of the lubrication performance of the drug mineralization gel prepared in Example 6 in different lubrication media; Figure 10 The in vitro drug release time-release rate curve of the drug mineralization gel prepared in Example 6; Figure 11 The in vitro degradation curve of the drug mineralization gel prepared in Example 6; Figure 12 This is a comparison diagram of the biocompatibility of the drug mineralization gel prepared in Example 6. Detailed Implementation

[0023] This invention provides a method for preparing a drug mineralization gel (see preparation flowchart). Figure 1 ), including the following steps: An aqueous solution of hydroxide was added dropwise to an aqueous solution of sodium alendronate to obtain a mixture; The mixture was then mixed with sodium hyaluronate to obtain a viscous liquid; The viscous liquid was added dropwise to an aqueous calcium source solution and stirred to obtain a hydrogel. The hydrogel was incubated to obtain a drug-mineralized gel.

[0024] Unless otherwise specified, the materials and equipment used in this invention are all commercially available products in the field.

[0025] In this invention, an aqueous hydroxide solution is added dropwise to an aqueous solution of sodium alendronate to obtain a mixture.

[0026] In this invention, the concentration of the alendronate sodium aqueous solution can be 10-30 mg / mL, or 15-25 mg / mL, specifically 10 mg / mL, 12 mg / mL, 15 mg / mL, 18 mg / mL, 20 mg / mL, 22 mg / mL, 25 mg / mL, 28 mg / mL, or 30 mg / mL. In this invention, the alendronate sodium aqueous solution is obtained by dissolving alendronate sodium in water; the water may include deionized water; the dissolution can be carried out under stirring conditions.

[0027] In this invention, the hydroxide in the aqueous hydroxide solution may include one or more of sodium hydroxide, potassium hydroxide, lithium hydroxide, and calcium hydroxide, specifically sodium hydroxide; the concentration of the aqueous hydroxide solution may be 50-100 mg / mL, or 60-90 mg / mL, specifically 50 mg / mL, 55 mg / mL, 60 mg / mL, 65 mg / mL, 70 mg / mL, 75 mg / mL, 80 mg / mL, 85 mg / mL, 90 mg / mL, 95 mg / mL, or 100 mg / mL. In this invention, the aqueous hydroxide solution is obtained by dissolving the hydroxide in water; the water may include deionized water; the dissolution may be carried out under stirring conditions.

[0028] In this invention, the dropping rate can be 1-5 mL / min, or 2-4 mL / min, and further, 3 mL / min; the dropping is carried out during stirring; and the pH value of the solution is monitored in real time using a precision pH meter during the dropping process. This invention, by adding an aqueous hydroxide solution to an aqueous alendronate sodium solution, can control the reaction rate and ensure uniform mixing. In this invention, the pH value of the system during the preparation of the mixture is 7-8, specifically 7, 7.2, 7.4, 7.5, 7.6, 7.8, or 8. Maintaining the pH value of the system at 7-8 during the preparation of the mixture stabilizes the chemical reaction process and ensures the stability of the quality and properties of the product.

[0029] After obtaining the mixture, the present invention mixes the mixture with sodium hyaluronate to obtain a viscous liquid.

[0030] In this invention, the number average molecular weight of the sodium hyaluronate can be 1,000,000 to 1,500,000, or 1,100,000 to 1,400,000, or even 1,200,000 to 1,300,000; the mass concentration of sodium hyaluronate in the viscous liquid can be 30 to 60 mg / mL, or 40 to 50 mg / mL, specifically 30 mg / mL, 35 mg / mL, 40 mg / mL, 45 mg / mL, 50 mg / mL, 55 mg / mL, or 60 mg / mL.

[0031] In this invention, the mixing can involve adding sodium hyaluronate to the mixture. This invention involves slowly adding sodium hyaluronate to the mixture, which helps ensure uniform dispersion and avoids the formation of insoluble particles, thereby improving the uniformity and stability of the final product.

[0032] After obtaining the viscous liquid, the present invention adds the viscous liquid dropwise to the calcium source aqueous solution, stirs and mixes to obtain a hydrogel.

[0033] In this invention, the calcium source in the calcium source aqueous solution may include one or more of calcium chloride, calcium nitrate, and calcium acetate, specifically calcium chloride; the concentration of the calcium source aqueous solution may be 400~600 mg / mL, or 450~550 mg / mL, specifically 400 mg / mL, 420 mg / mL, 450 mg / mL, 480 mg / mL, 500 mg / mL, 520 mg / mL, 550 mg / mL, 580 mg / mL, or 600 mg / mL.

[0034] The present invention does not have a special limitation on the stirring and mixing time; stirring and mixing is sufficient to obtain a white hydrogel.

[0035] After obtaining the hydrogel, the present invention incubates the hydrogel to obtain a drug mineralization gel.

[0036] In this invention, the incubation temperature can be 25~45℃, or 30~40℃, specifically 25℃, 28℃, 30℃, 32℃, 35℃, 37℃, 40℃, 42℃, or 45℃; the incubation time can be 0~7h, or 1~6h, specifically 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 5.5h, 6h, 6.5h, or 7h; the incubation can be performed by transferring the hydrogel to a sterile petri dish and placing it in a constant temperature incubator.

[0037] In this invention, the mass percentage of sodium alendronate in the drug mineralization gel can be 1-5%, or 2-4%, specifically 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5% or 5%.

[0038] This invention utilizes sodium alendronate (ADA) and Ca 2+ Mixing to form ADA-Ca 2+ Metal-organic framework (MOF)-like crystals, hydrogel (HA-ADA-Ca), undergo dynamic mechanical changes during incubation. The Ca in the HA-ADA-Ca hydrogel... 2+ The carboxylic acid group (-COO-) of sodium hyaluronate (HA) and the phosphonic acid group (-PO3) of sodium alendronate (ADA) 2- All of them undergo coordination, and the introduction of ADA promotes the deposition of calcium phosphate mineralization phase through P-Ca interaction, thus endowing the drug mineralized gel with mechanical properties and biological activity.

[0039] The present invention also provides a drug mineralization gel prepared by the preparation method described in the above technical solution.

[0040] This invention also provides the application of the drug-mineralized gel described above in the preparation of biomedical gel materials. In this invention, the biomedical gel material includes injectable joint lubricants (such as… Figure 1 (As shown).

[0041] The drug-mineralized gel prepared by this invention exhibits excellent lubrication properties. Due to the hydrophilicity of the polymer chains (sodium hyaluronate) and the water-binding capacity of the gel network, the hydrogel can form a hydrated film layer during lubrication, reducing the coefficient of friction and thus achieving a good lubrication effect. This effectively reduces the coefficient of friction on the joint surface and minimizes cartilage wear. The drug-mineralized gel prepared by this invention also has excellent injectability, exhibiting a fluid dynamic state at room temperature. It can be easily injected into the joint cavity using a conventional syringe, making the procedure convenient and minimally invasive. Furthermore, the drug-mineralized gel prepared by this invention possesses stable drug-release properties. The drug, alendronate sodium, can be stably loaded through mineralization and gradually released as the gel slowly degrades, prolonging the drug's duration of action and improving therapeutic efficacy. Finally, the drug-mineralized gel prepared by this invention exhibits good biocompatibility. All raw materials used are biocompatible and have no significant cytotoxicity, making it unlikely to trigger a foreign body reaction in the joint cavity after injection.

[0042] To further illustrate the present invention, the following detailed description, in conjunction with embodiments, provides a drug mineralization gel, its preparation method, and its application, but these descriptions should not be construed as limiting the scope of protection of the present invention.

[0043] In the following examples, unless otherwise specified, the ambient temperature is room temperature (20°C). The rheological property testing method involves placing sheet-like hydrogel samples with a diameter of 35 mm and a thickness of 0.5–1.2 mm onto a top plate geometry with a diameter of 35 mm. Rotational flow slope tests are performed at shear rates of 1–1000 L / s. Shear storage modulus (G') and loss modulus (G'') are measured at a frequency of 1 Hz and a shear stress of 1000 Pa. The compressive strength testing method involves using a cylindrical hydrogel sample with a height of 4 mm and a diameter of 5 mm on a universal testing machine equipped with a 500 N load sensor. The measured value of compressive stress is F / A0, where F is the force and A0 is the initial contact area; the estimated value of compressive strain is h / h0, where h and h0 are the deformed height and the initial height, respectively; the compressive modulus is calculated from the slope of a curve representing strain from 0 to 10%. All mechanical tests are performed after the gel reaches swelling equilibrium and at least three times per group, with the average value used as the test result.

[0044] Example 1 Sodium hydroxide (NaOH) was dissolved in deionized water to obtain a NaOH aqueous solution (100 mg / mL); sodium alendronate (ADA) was dissolved in deionized water to obtain an ADA aqueous solution (20 mg / mL); anhydrous calcium chloride (CaCl2) was dissolved in deionized water to obtain a CaCl2 aqueous solution (500 mg / mL); 25 μL of the NaOH aqueous solution was added dropwise to 1 mL of the ADA aqueous solution. 50 mg of sodium hyaluronate (HA) powder was added to the above mixture. Then, 24 μL of the CaCl2 aqueous solution was added, and a white hydrogel was immediately formed. The hydrogel was incubated in a constant temperature oven at 25°C for 7 hours to obtain a drug mineralization gel. The drug mineralization gel prepared in this example has a storage modulus of 2704.53 Pa and a loss modulus of 1038.64 Pa.

[0045] Example 2 The drug mineralization gel was prepared according to the method of Example 1, the only difference being the incubation temperature of 37°C. The storage modulus of the drug mineralization gel prepared in this example was 14757.31 Pa, and the loss modulus was 4638.78 Pa.

[0046] Example 3 The drug mineralization gel was prepared according to the method of Example 1, the only difference being the incubation temperature of 45°C. The drug mineralization gel prepared in this example has a storage modulus of 3149.96 Pa and a loss modulus of 1641.39 Pa.

[0047] Figure 2 The rheological properties of the drug mineralization gels described in Examples 1-3 are as follows: Figure 2 It can be seen that the viscoelasticity of the drug mineralized gel at 25℃, 37℃ and 45℃ remains stable over time, but the incubation temperature has a significant regulatory effect on the viscoelasticity. As the incubation temperature increases, the storage modulus and loss modulus of the drug mineralized gel first increase and then decrease.

[0048] comprehensive Figure 2 The rheological properties test results show that the structure of the drug mineralization gel is more stable when the incubation temperature is 37℃.

[0049] Example 4 The drug mineralization gel was prepared according to the method of Example 1, the only difference from Example 1 being that the incubation temperature was 37°C and the incubation time was 0h.

[0050] The drug mineralization gel prepared in this embodiment has a compressive strength of 3.06 kPa and a compressive modulus of 3.91 kPa under a compression of 50%; after incubation in a constant temperature oven at 37°C for 0 h, the storage modulus is 4.19 kPa.

[0051] Example 5 The drug mineralization gel was prepared according to the method of Example 4, the only difference from Example 4 being that the incubation temperature was 37°C and the incubation time was 3 hours.

[0052] The drug mineralization gel prepared in this embodiment has a compressive strength of 7.14 kPa, a compressive modulus of 6.51 kPa, and a storage modulus of 5.27 kPa under a compression of 50%.

[0053] Example 6 The drug mineralization gel was prepared according to the method of Example 4, the only difference from Example 4 being that the incubation temperature was 37°C and the incubation time was 7 hours.

[0054] The drug mineralization gel prepared in this embodiment has a compressive strength of 12.68 kPa, a compressive modulus of 15.6 kPa, and a storage modulus of 12.94 kPa under a compression of 50%.

[0055] Figure 3 The rheological properties test results of the drug mineralization gels described in Examples 4-6 are from... Figure 3 It can be seen that the modulus of the drug mineralization gel at 37°C increases with the increase of incubation time. When the incubation time is 0~7h, the modulus of the drug mineralization gel increases from 4.19kPa to 12.94kPa.

[0056] Figures 4-5 The compression properties of the drug mineralized gels described in Examples 4-6 are given by... Figures 4-5 It can be seen that the compressive strength and compressive modulus of the drug mineralized gel at 37°C both increase with the increase of incubation time, with the compressive strength increasing from 3.06 kPa to 12.68 kPa and the compressive modulus increasing from 3.91 kPa to 15.6 kPa.

[0057] comprehensive Figures 3-5 The results of rheological and compressive property tests show that the drug mineralization gel obtained after incubation at 37℃ for 7 hours has the best performance.

[0058] Figure 6 The stress and modulus statistics of the drug mineralization gels prepared in Examples 4-6 are presented by [the relevant authority / organization]. Figure 6It was observed that, with prolonged incubation at 37°C, the unincubated hydrogel exhibited typical mechanical properties of a soft material, with a compressive stress of 0.99 kPa and an elastic modulus (Ec) of 3.43 kPa at 50% strain. Conversely, after 7 hours of incubation, the compressive stress of the hydrogel increased significantly, reaching as high as 15.57 kPa. This obvious soft-to-hard mechanical transition indicates a significant change in the cross-linked structure of the hydrogel before and after incubation. These results suggest that the strength and modulus of the hydrogel improve to some extent with prolonged incubation at 37°C. The increased compressive stress indicates that the polymer interactions have shifted from dynamic covalent bonds to stable covalent bonds.

[0059] Figure 7 The drug mineralization gel prepared in Example 6 was subjected to different loadings (0.5N, 1N, 1.5N, 2N, and 3N, at a frequency of 20 min). -1 Lubrication performance at a temperature of 20℃, by Figure 7 It can be seen that the friction coefficients of the drug mineralization gel under applied loads of 0.5N, 1N, 1.5N, 2N and 3N are 0.033±0.004, 0.031±0.002, 0.026±0.002, 0.024±0.003 and 0.027±0.002, respectively.

[0060] Figure 8 The drug mineralization gel described in Example 6 was tested at different frequencies (1 min). -1 10min -1 20min -1 30min -1 and 50min -1 The lubrication performance under constant normal force of 1N and temperature of 20℃ is determined by... Figure 8 It can be seen that the drug mineralization gel, after 1 minute of application -1 10min -1 20min -1 30min -1 and 50min -1 The coefficients of friction at the specified frequencies were 0.050±0.006, 0.021±0.004, 0.031±0.003, 0.043±0.004, and 0.085±0.006, respectively.

[0061] Figure 9 The lubrication performance of the drug mineralization gel described in Example 6 under different lubrication media (constant normal force of 1N, frequency of 20min) -1 (at a temperature of 20℃), by Figure 9It can be seen that the coefficients of friction of the drug mineralization gel in deionized water (DI water), simulated body fluid (SBF), physiological saline (SPSS), bovine serum albumin (BSA), and phosphate buffered saline (PBS) are 0.031±0.003, 0.027±0.005, 0.027±0.007, 0.037±0.007, and 0.052±0.004, respectively.

[0062] 300 mg of the drug-mineralized gel was immersed in 1 mL of deionized water and incubated at 37°C. At predetermined time points, the supernatant was collected and 1 mL of fresh deionized water was added. Using a UV-Vis spectrophotometer, the maximum absorption wavelength of alendronate sodium was determined to be 276 nm. A correlation was established between concentration (C) and absorbance intensity at 276 nm (Ig). 42 The linear regression of nm) yields the standard curve equation as: I 276 = 0.9634C + 0.07805. The release rate at each time point was calculated based on the standard curve. The cumulative release percentage Q of diclofenac sodium is calculated as follows: Q = (m0 + m1) / m = [(C1 + C2 + ... + C...] n V0+C n [V1] / n. Here, m is the total mass of diclofenac sodium, m0 is the mass of diclofenac sodium removed from the drug at each predetermined time point, m1 is the mass of diclofenac sodium in the drug, n is the total amount of diclofenac sodium, V0 is 4 mL, V1 is 100 mL, C n Concentration at each predetermined time point. Figure 10 The results of the in vitro drug release assessment (release time-release rate curve) of the drug mineralization gel described in Example 6 were obtained from... Figure 10 The prepared drug-mineralized gel loaded with alendronate sodium showed a cumulative release of 52.4% within 10 hours in PBS solution. The drug release experiment results indicate that the drug-mineralized gel encapsulated with diclofenac sodium exhibits excellent sustained drug release capability in PBS solution, which may contribute to a more prolonged anti-inflammatory effect in the treatment of arthritis.

[0063] Figure 11 The in vitro degradation evaluation results of the drug mineralization gels described in Examples 4-6 are from... Figure 11 It was found that the swelling behavior of the drug-mineralized gel led to an increase in its mass during the first 10 hours, followed by a decrease in PBS solution. Comparing hydrogels cultured at 37°C for 0, 3, and 7 hours, the degradation rate was slow in all cases. The hydrogel cultured for 7 hours retained 140.87833 ± 1.4296% of its original weight after immersion in PBS solution for 60 hours. This is due to the presence of stable crystals within the hydrogel, which maintain stability even after immersion in PBS for 60 hours.

[0064] The sterile drug mineralization gel was placed in DMEM complete medium (gel mass to medium volume ratio of 0.1 g / mL) and extracted at 37℃ and 5% CO2 for 24 h. The supernatant was collected and filtered to obtain a sterile extract. Figure 12 To compare the biocompatibility of the drug-mineralized gel described in Example 6, cells were digested with 0.25 wt% trypsin after washing with PBS, and the cell density in the suspension was adjusted to 5 × 10⁻⁶ cells using an electronic cell counting chamber. 4 Cells were cultured at a density of 100 μL / well, and then the cell suspension was evenly seeded into 96-well plates (100 μL / well). After seeding, the experimental areas were marked for 1, 3, and 5 days. The culture plates were pre-cultured in an incubator (37℃, 5% CO2) for 24 h. After the cells adhered to the plates, 100 μL of bacterial filtrate gel extract was added to each well to replace the culture, and the cells were measured at the marked time points of 1, 3, and 5 days. Figure 12 It can be seen that, regardless of the extraction time, the cell viability of the hydrogel is basically the same as that of the control group.

[0065] In summary, the drug-mineralized gel prepared by this invention possesses excellent injectability, lubrication properties, long-lasting drug release capability, and good biocompatibility. It exhibits excellent therapeutic effects on osteoarthritis and can be used to prepare drug-mineralized gels, particularly injectable joint lubricants. When injected into the joint cavity via a syringe, the drug-mineralized gel prepared by this invention rapidly gels, reducing the joint surface friction coefficient to 0.02-0.04. The drug is released continuously as the gel slowly degrades, without any burst release issues. This invention not only lubricates joints and reduces friction but also alleviates joint inflammation, effectively improving joint function, and has extremely high application value in the treatment of osteoarthritis. Furthermore, the raw materials used in this invention meet safety standards (chondrocyte survival rate ≥80%, no foreign body reaction), simultaneously achieving lubrication, anti-inflammation, and cartilage repair, demonstrating excellent prospects for widespread application.

[0066] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.

Claims

1. A method for preparing a drug mineralization gel, characterized in that, Includes the following steps: An aqueous solution of hydroxide was added dropwise to an aqueous solution of sodium alendronate to obtain a mixture; The mixture was then mixed with sodium hyaluronate to obtain a viscous liquid; The viscous liquid was added dropwise to an aqueous calcium source solution and stirred to obtain a hydrogel. The hydrogel was incubated to obtain a drug-mineralized gel.

2. The preparation method according to claim 1, characterized in that, The hydroxide in the aqueous hydroxide solution includes one or more of sodium hydroxide, potassium hydroxide, lithium hydroxide, and calcium hydroxide; The concentration of the hydroxide aqueous solution is 50~100 mg / mL.

3. The preparation method according to claim 1, characterized in that, The concentration of the sodium alendronate aqueous solution is 10~30 mg / mL.

4. The preparation method according to claim 1, characterized in that, The calcium source in the calcium source aqueous solution includes one or more of calcium chloride, calcium nitrate and calcium acetate. The concentration of the calcium source aqueous solution is 400~600 mg / mL.

5. The preparation method according to claim 1, characterized in that, The pH value of the system during the preparation of the mixture is 7-8.

6. The preparation method according to claim 1, characterized in that, The number-average molecular weight of the sodium hyaluronate is 1,000,000 to 1,500,000. The mass concentration of sodium hyaluronate in the viscous liquid is 30~60 mg / mL.

7. The preparation method according to claim 1, characterized in that, The incubation temperature is 25~45℃, and the time is 0~7h.

8. The drug mineralization gel prepared by the preparation method according to any one of claims 1 to 7.

9. The application of the drug mineralization gel according to claim 8 in the preparation of biomedical gel materials.

10. The application according to claim 9, characterized in that, The biomedical gel material includes injectable joint lubricants.